Literature DB >> 30326993

Cryptic severe Plasmodium falciparum malaria in a Moroccan man living in Tuscany, Italy, August 2018.

Lorenzo Zammarchi1,2, Nicoletta Di Lauria2, Filippo Bartalesi1, Lorenzo Roberto Suardi2, Giampaolo Corti1,2, Jessica Mencarini2, Daniela Boccolini3, Carlo Severini3, Luigi Gradoni3, Carla Buonamici4, Giorgio Garofalo4, Anna Maria Bartolesi5, Nunziata Ciccone5, Andrea Berni6, Loredana Poggesi6,2, Fabrizio Niccolini7, Gian Maria Rossolini5,2, Roberto Romi3, Alessandro Bartoloni1,2.   

Abstract

In August 2018 a Moroccan man living in Tuscany developed Plasmodium falciparum malaria. The patient declared having not recently visited any endemic country, leading to diagnostic delay and severe malaria. As susceptibility to P. falciparum of Anopheles species in Tuscany is very low, and other risk factors for acquiring malaria could not be completely excluded, the case remains cryptic, similar to other P. falciparum malaria cases previously reported in African individuals living in Apulia in 2017.

Entities:  

Keywords:  Anopheles spp.; Europe; Italy; Plasmodium falciparum; autochthonous; malaria

Mesh:

Substances:

Year:  2018        PMID: 30326993      PMCID: PMC6194912          DOI: 10.2807/1560-7917.ES.2018.23.41.1800527

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


A case of severe Plasmodium falciparum malaria was diagnosed in August 2018 in a Moroccan man living in Tuscany, Italy. Malaria was initially not considered by the managing clinicians because the patient reported to have not recently visited any endemic country, leading to diagnostic delay and severe anaemia. Here we describe the clinical and epidemiological features of this case and discuss different hypotheses on the possible route of transmission.

Case report

A previously healthy Moroccan man in his late 40s was admitted to an internal medicine ward of a tertiary hospital in Florence, Italy, in mid-August 2018, with a 3-day history of high fever (> 38.5°C), headache, and mild cough. At physical examination, jaundice and splenomegaly were observed. Blood tests showed thrombocytopenia, haemolytic anaemia, and increased inflammatory markers (Table). A haematological disease was suspected, while malaria was initially not considered, since the patient declared to have not recently visited any endemic area. On Day 4 after admission, investigation for malaria was requested following an infectious diseases consultation. Thin blood smears revealed the presence of P. falciparum trophozoites with a parasitaemia of 0.5%. PCR confirmed P. falciparum mono-infection. The patient was referred to the Infectious and Tropical Diseases Unit with the diagnosis of severe malaria (haemoglobin (Hb) < 7 g/dL and parasitaemia > 0.2% [1]), and intravenous artesunate was administered for 2 days, followed by oral dihydroartemisin-piperaquine for 3 days. Two units of packed red blood cells were transfused. The patient's conditions improved and he was discharged a few days later. The case was notified to public health authorities (malaria is a mandatory notifiable disease in Italy) and microscopically confirmed by the National Institute of Health, Rome, Italy [2].
Table

Summary of main blood and urine investigations performed in the patient with Plasmodium falciparum malaria, Tuscany, Italy, August 2018

ParametersTime after admission (Day 1) at the hospital in August 2018
Day 1Day 2Day 3Day 4Day 5Day 6
White blood cells (x10^9/L) (norm: 4.00–10.00)6.194.314.873.013.914.51
Haemoglobin (g/dL) (norm: 14–18)12.110.59.76.98.98.8
Haematocrit (%) (norm: 42.0–52.0)34.63027.719.925.725.9
Platelet count (x10^9/L) (norm: 14–440)65447079101261
Prothrombin time (%)(norm: 70–130)62616970NDND
INR (norm: 0.8–1.2)1.41.41.31.3NDND
Partial thromboplastin time (sec) (norm: 22–38)27.127.527.727.1NDND
Fibrinogen (mg/dL) (norm: 200–400)597668709462NDND
Glucose (mg/dL) (norm: 65–110)117102105NDND82
Creatinine (mg/dL) (norm: 0.44–0.9 )0.920.930.970.910.770.69
Sodium (mEq/L) (norm: 135–145)135133134136139139
Potassium (mEq/L) (norm: 3.5–5)ND3.43.83.643.9
Alanine aminotransferase (U/L) (norm: 12–65)5340NDND4018
Total bilirubin (mg/dL) (norm: 0.2–1)3.23.14.22.0NDND
LDH (U/L) (norm: 84–246)ND640866ND733ND
Haptoglobin (g/L) (norm: 0.3–2.0)ND< 0.078NDNDNDND
C-reactive protein (mg/L) (norm: <9)148NDNDND88ND
Procalcitonin (ng/mL) (norm: <0.5)NDND5.09ND1.20ND
Reticulocyte count (%) (norm: 0.5–2.5)ND4.8NDNDNDND
HIV 1–2 Ag/Ag (norm: neg)ND ND NDNegNDND
Urine screening test for drugsa (norm: neg)ND NDND NegNDND

Ag: antigen; HIV: human immunodeficiency virus; INR: international normalised ratio; LDH: lactate dehydrogenase; ND: not done; Neg: negative.

a Including amfetamine, benzodiazepine, cocaine, ecstasy, marijuana, methadone, opiates.

Ag: antigen; HIV: human immunodeficiency virus; INR: international normalised ratio; LDH: lactate dehydrogenase; ND: not done; Neg: negative. a Including amfetamine, benzodiazepine, cocaine, ecstasy, marijuana, methadone, opiates.

Epidemiological investigation

A careful history on possible malaria exposure was collected in collaboration with a Moroccan cultural mediator. The patient was born and had grown up in the Marrakesh-Safi Region, Morocco, before moving to Italy in 1990. He currently lives in an urbanised area of the province of Florence, Italy, about 10 km away from the city centre, where has been working, discontinuously, as a construction worker. He denied previous blood transfusions and intravenous drug use. He reported a 1-month travel to Ghana looking for a job in 2014. On that occasion, upon his arrival at Accra airport, he received an injection (probably, yellow fever vaccine) and was provided with some tablets (possibly antimalarial drug) that he took for about one week. During his stay in Ghana and thereafter, he did not present febrile diseases. He reported two to three travels to Morocco per year, to visit relatives in his village of origin for periods of up to 2 months. He returned from his last travel to Morocco, arriving by plane from Marrakech to Pisa in early June 2018, 73 days before the onset of symptoms. He slept one night in his residence near Florence, then moved by train to Viareggio, and subsequently worked outside as a beach vendor on the Tuscan coast during the summer. He stayed at the seaside and slept outdoors on the beach or in nearby places (for example in the pine forests along the coast, just behind the sand dunes), together with other beach vendors, including persons from Sub-Saharan Africa. The patient remembered many mosquito bites. He changed his location daily gradually moving south, and recalled having worked in beach resorts of Cecina, San Vincenzo, and Piombino, while he was not certain to have reached more southern beaches in the Maremma area. He returned to the starting point in Viareggio in mid-August. Then, he spent some time in a village near Bologna, and finally reached his home, 2 days later when he started to have fever in the afternoon. Over the whole summer, the patient worked and travelled with a group of newly-arrived men from Morocco who returned to their country on the day of fever onset in the patient; according to him all were in good health. No other information about them was available.

Discussion

Until the end of the 19th century, malaria was endemic in Italy, and the disease was responsible for ca 2 million cases and 15,000–20,000 deaths per year [3]. The most affected areas were the Southern and Central Regions (including the Maremma area in the Tuscany Region), Sicily, and Sardinia [3-5]. P. falciparum malaria accounted for ca 20–30% of cases in several regions including in the Maremma area of Tuscany [3]. At that time the proven mosquito vectors present in Italy were Anopheles labranchiae, An. sacharovi, and An. superpictus [6]. Several initiatives to control malaria and its vectors were implemented during the 20th century, including the reclamation of swamps, the extensive use of chemical pesticides, and the extensive delivery of quinine to the population [7]. These initiatives successfully led to a dramatic reduction of anopheline mosquitoes and to the elimination of the disease in 1970 [5]. Following the elimination, an increasing number of imported cases were reported in the country, in parallel to the rise of international travel and migratory flows, with ca 800 cases per year in the last two years [8]. An autochthonous introduced case of P. vivax malaria acquired in the Maremma area, Grosseto, Tuscany Region was recorded in August 1997 [9]. In that case, the source of the infection was identified to be a parasitemic Indian girl living about 500 m away from the patient’s residence, who had recently returned from a travel to her country of origin [9]. Several mosquito-breeding sites with An. labranchiae were identified during the entomological surveillance activities [9]. In separate events, another two potentially autochthonous introduced P. vivax malaria cases were diagnosed, one in August 2009 and one in September 2011, however their source of infection remained unidentified [10]. The patients had likely been infected in the Agro Pontino area, Latium Region (2009 case), and in the Cosenza province, Calabria Region (2011 case), respectively. Entomological investigations were able to detect the presence of An. maculipennis s.s. and An. labranchiae in the two episodes, respectively [10]. In October 2017, four P. falciparum malaria cases were reported in the Apulia Region, in three Moroccan and one Sudanese immigrants without recent history of travel outside Italy (some of them visited Morocco previously) [7,11]. All the affected patients were farm workers in the Ginosa or Castellaneta countryside, Taranto province [11,12], where the presence of An. labranchiae was confirmed by an entomological survey. All cases declared to have been in Italy for more than 3 months prior to onset of symptoms [11,13]. Based on these findings, the European Centre for Disease Prevention and Control published two reports [11,14], and the United States Centers for Diseases Control and Prevention recommended ‘mosquito avoidance precaution’ to travellers to agricultural areas of Ginosa [13]. In this report we describe a cryptic severe P. falciparum malaria case observed in a Moroccan person living in Tuscany, Italy. Morocco was certified as malaria free country in 2010, not reporting autochthonous cases since 2007 [15]. Imported P. falciparum malaria cases, mainly from Sub-Saharan Africa, are reported, and a risk of reintroduction is considered [16,17]. Our patient presented symptoms 73 days after leaving Morocco, making it unlikely that the infection was acquired in Morocco since the incubation period for P. falciparum ranges in most cases from 9 to 30 days [18]. The possibility that the patient had been infected during a previous 1-month stay in Ghana, in 2014, and had developed the disease after such a long incubation period appears unlikely, although it cannot be completely ruled out, as prolonged incubation has been reported in the recent literature [19]. On rare occasions, cases of P. falciparum malaria with delayed onset have been described in semi-immune migrants from endemic areas in which the immunity tends to wane years after migration [20]. The possibility of ‘airport malaria’ could be excluded, since the nearest airports to the Tuscany coast (Pisa and Grosseto) are at least ca 15 km far from the patient visited areas. Other travels to endemic areas and risk factors for induced malaria such as transfusion, transplant, nosocomial, intravenous drug use were denied by the patient. The possibility of transmission by an infected mosquito transported in a baggage cannot be excluded [21]. Malaria competent vectors are present in Italy and, according to the latest available entomological data, An. labranchiae is present in Tuscany [10]. The level of competence of An. labranchiae to transmit P. falciparum is debated. Studies conducted on vectorial capacity of Italian An. labranchiae showed that the species is poorly susceptible to infection with tropical or African P. falciparum strains [22-24]. Moreover, a study from 2012 assessed the malariogenic potential of the Maremma as very low, although the occurrence of sporadic, isolated cases of introduced P. vivax malaria was considered possible during the summer season, in presence of asymptomatic gametocyte carriers from endemic areas [24]. Concerning P. falciparum, the estimated vectorial capacity of anopheline population in Maremma is considered even lower [24]. The presented case, together with other P. falciparum malaria cases recently reported from Apulia, may suggest the occurrence of sporadic autochthonous P. falciparum during the summer season in Italy. However, considering that the susceptibility to P. falciparum infection of the anthropophilic Anopheles species present in Tuscany area is very low, and that the possibility of unrevealed risk factors for acquiring malaria cannot be completely excluded, the presented case remains cryptic. Some travellers may inadvertently or deliberately fail to mention that they have recently been in an endemic area [25]. The fact that four patients recently diagnosed with P. falciparum malaria in Italy were Moroccan citizens remains difficult to explain, considering that Morocco is a malaria-free country. In our patient, malaria diagnosis was delayed because of the missing history of a recent visit to a malaria endemic area. In this perspective, clinicians should consider malaria as one possible differential diagnosis in patients with compatible clinical and laboratory features, even if they do not report a clear exposure to endemic countries.
  11 in total

1.  [Malaria in Morocco: from pre-elimination to elimination, what risks for the future?].

Authors:  B Trari; P Carnevale
Journal:  Bull Soc Pathol Exot       Date:  2011-06-03

2.  Autochthonous falciparum malaria possibly transmitted by luggage-carried vector in Paris, France, February 2013.

Authors:  S Gallien; F Taieb; S Hamane; N De Castro; J M Molina
Journal:  Euro Surveill       Date:  2013-10-03

3.  Malaria in Italy - Migrants Are Not the Cause.

Authors:  Giovanni Benelli; Marco Pombi; Domenico Otranto
Journal:  Trends Parasitol       Date:  2018-02-03

4.  Receptivity to malaria in Europe.

Authors:  J de Zulueta; C D Ramsdale; M Coluzzi
Journal:  Bull World Health Organ       Date:  1975       Impact factor: 9.408

5.  [Assessment of malaria resurgence risk in Morocco. Study of the vectorial capacity of Anopheles labranchiae in a rice cultivation area in the north of the country].

Authors:  C Faraj; S Ouahabi; E Adlaoui; D Boccolini; R Romi; R El Aouad
Journal:  Parasite       Date:  2008-12       Impact factor: 3.000

6.  Probable autochthonous introduced malaria cases in Italy in 2009-2011 and the risk of local vector-borne transmission.

Authors:  R Romi; D Boccolini; M Menegon; G Rezza
Journal:  Euro Surveill       Date:  2012-11-29

7.  Malaria in Maremma, Italy.

Authors:  M Baldari; A Tamburro; G Sabatinelli; R Romi; C Severini; G Cuccagna; G Fiorilli; M P Allegri; C Buriani; M Toti
Journal:  Lancet       Date:  1998-04-25       Impact factor: 79.321

8.  Clinical aspects of uncomplicated and severe malaria.

Authors:  Alessandro Bartoloni; Lorenzo Zammarchi
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-05-04       Impact factor: 2.576

9.  Assessment of the risk of malaria re-introduction in the Maremma plain (Central Italy) using a multi-factorial approach.

Authors:  Roberto Romi; Daniela Boccolini; Roberto Vallorani; Francesco Severini; Luciano Toma; Maurizio Cocchi; Angelo Tamburro; Gianni Messeri; Antonio Crisci; Luca Angeli; Roberto Costantini; Irene Raffaelli; Giorgio Pontuale; Isabelle Thiéry; Annie Landier; Gilbert Le Goff; Anna Maria Fausto; Marco Di Luca
Journal:  Malar J       Date:  2012-03-30       Impact factor: 2.979

Review 10.  The duration of Plasmodium falciparum infections.

Authors:  Elizabeth A Ashley; Nicholas J White
Journal:  Malar J       Date:  2014-12-16       Impact factor: 2.979

View more
  1 in total

1.  Letter to the editor: Is malaria re-emerging in southern Europe? Cryptic Plasmodium falciparum malaria in Malta, October 2018.

Authors:  Raquel Medialdea-Carrera; Tanya Melillo; Charmaine Gauci; Graziella Rocco; Maria Louise Borg
Journal:  Euro Surveill       Date:  2018-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.